Review
Diplomatic immunity: turning a foe into an ally
Affiliations
- PMID: 19169955
Item in Clipboard
Review
Diplomatic immunity: turning a foe into an ally
Curr Opin Mol Ther.
2009 Feb.
Abstract
Striking a balance between subversion of antiviral immune responses and enhancement of potentially therapeutic, antitumor cytotoxic responses is a challenge at the forefront of oncolytic virus (OV) research. Some of the immune hurdles that must be overcome to maximize OV delivery to spread throughout tumor beds, and an outline of some of the strategies developed to deal with these obstacles are reviewed. In addition, current research that may lead to antitumor immunity during, or subsequent to, OV therapy is discussed. Finally speculations are made upon emerging areas of viral and immune research that could be merged to create new therapeutic paradigms.
Similar articles
-
Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?Curr Opin Mol Ther. 2008 Feb;10(1):32-7. Curr Opin Mol Ther. 2008. PMID: 18228179 Review.
-
Combining oncolytic virotherapy and tumour vaccination.Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):143-8. doi: 10.1016/j.cytogfr.2010.02.009. Epub 2010 Mar 11. Cytokine Growth Factor Rev. 2010. PMID: 20226716 Review.
-
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.Trends Immunol. 2018 Mar;39(3):209-221. doi: 10.1016/j.it.2017.11.006. Epub 2017 Dec 20. Trends Immunol. 2018. PMID: 29275092 Review.
-
The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies.Cell Microbiol. 2009 Jun;11(6):889-97. doi: 10.1111/j.1462-5822.2009.01317.x. Epub 2009 Apr 20. Cell Microbiol. 2009. PMID: 19388908 Review.
-
Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy.Gene Ther. 2008 May;15(10):772-9. doi: 10.1038/gt.2008.40. Epub 2008 Mar 27. Gene Ther. 2008. PMID: 18369325 Review.
Cited by
-
Potentiating prostate cancer immunotherapy with oncolytic viruses.Nat Rev Urol. 2018 Apr;15(4):235-250. doi: 10.1038/nrurol.2018.10. Epub 2018 Feb 13. Nat Rev Urol. 2018. PMID: 29434366 Review.
-
Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.Mol Ther. 2012 Sep;20(9):1689-1698. doi: 10.1038/mt.2012.83. Epub 2012 May 1. Mol Ther. 2012. PMID: 22547150 Free PMC article.
-
Oncolytic immunotherapy: where are we clinically?Scientifica (Cairo). 2014;2014:862925. doi: 10.1155/2014/862925. Epub 2014 Jan 16. Scientifica (Cairo). 2014. PMID: 24551478 Free PMC article. Review.
-
Antibody neutralization of retargeted measles viruses.Virology. 2014 Apr;454-455:237-46. doi: 10.1016/j.virol.2014.01.027. Epub 2014 Mar 14. Virology. 2014. PMID: 24725950 Free PMC article.
-
Is the immune response a friend or foe for viral therapy of glioma?Neuro Oncol. 2017 Jul 1;19(7):882-883. doi: 10.1093/neuonc/nox082. Neuro Oncol. 2017. PMID: 28874006 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources